Demographic trends, such as population growth and ageing, coupled with medical progress and rising prosperity are key growth drivers in the healthcare and medtech sectors. In addition, an unmet medical need for new therapies in many diseases still remains. Understanding the viability and the commercialisation potential of new therapies and technical solutions is key.
On healthcare and medtech related projects, Lilja Capital works closely with our industry sector experts.
Daniela Bosshardt is the Chairwoman of Galenica, a Swiss publicly traded healthcare provider and a member of the board of Reprisk. She is formerly a board member of ViforPharma, Verve Capital Partners and Nobel Biocare. Daniela is an ETH trained pharmacist and a former financial analyst in the healthcare sector.
Dr. Felix Dahm and Dr. Gabriel Markson are co-founders of E3 Life, a life science Investment and M&A Advisory firm based in Zug, Switzerland. They previously held senior management positions at private equity portfolio companies BSN medical, Gambro and Nycomed achieving outsized returns for the owners.
In total, Felix and Gabriel have executed over 20 M&A transactions – on the buy-side as well as on the sell-side – with total transaction value in excess of €15 billion. They combine deep scientific and clinical knowledge with extensive commercial experience.